Virtual Investor Conference

Psychedelics for Obesity

June 12, 2023

Clearmind is proud to host Professor Tam to discuss the challenges of obesity, and the promising pre-clinical results for MEAI as a potential treatment.


Prof. Joseph Tam, DMD, PhD

Head of the Obesity and Metabolism Laboratory, Hebrew University

Prof. Tam led the pre-clinical studies for MEAI at his lab at the Hebrew University. His postdoctoral studies have explored the biological mechanisms underlying obesity and metabolic syndrome at the National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the NIH. Joseph is Associate Professor of Pharmacology at the Hebrew University’s Institute for Drug Research.

Adi Zuloff-Shani, PhD

Clearmind's Chief Executive Officer

Dr. Adi Zuloff-Shani is a biomedical research and development executive with over 20 years of strategic and operational leadership in the healthcare industry, and a deep understanding of therapeutics development in heavily regulated environments.

Adjunct Prof. Mark Haden

Clearmind's VP of Business Development

Previously the Executive Director of MAPS Canada for 10 years, Mark is an adjunct professor at the University of British Columbia's School of Population and Public Health, and has published on the issue of drug control policy and psychedelics. Mark also worked in the addictions field in counselling, supervisory and management positions for 28 years.


Shannon Smadella

Wellness Personality & Podcast Host, Executive Consultant, Former Miss Canada

Shannon has interviewed some of the most prominent leaders, scientists, doctors and thinkers in the psychedelic space. She was the host/co-organizer of Seasons 1 & 2 of "Examining The Psychedelic Renaissance" with MAPS Canada and the Inaugural World Psychedelics Day [6.20] She has worked in business for the past 20 years, raising millions for various charities & organizations, including those in psychedelics.